AN2 Therapeutics Inc (ANTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $172.64M
Last updated: Nov 17, 2026 at 11:04 AM ET
AN2 Therapeutics Inc (ANTX) Earnings: Report Dates and Results
AN2 Therapeutics (ANTX) is expected to report earnings on Mar 15, 2027. In the quarter ended Sep 30, 2026, AN2 Therapeutics reported EPS of -$0.17, above the -$0.20 estimate. It beat the EPS estimate in 4 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
ANTX has an expected report date of Mar 15, 2027.
Earnings History
Of the 19 quarters below that had an estimate, ANTX beat 11 and missed 8. The widest gap in the table came in the quarter ended Mar 31, 2022, when EPS landed 484.31% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported |
|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.17 | -$0.20 | -$0.20 - -$0.20 | +15.00% | Beat | N/A | 2 | N/A | Nov 9, 2026 |
| Jun 30, 2026 | -$0.18 | -$0.24 | -$0.25 - -$0.23 | +25.00% | Beat | N/A | 2 | 1 up, 0 down | Aug 11, 2026 |
| Mar 31, 2026 | -$0.29 | -$0.23 | -$0.23 - -$0.23 | -26.09% | Miss | N/A | 1 | 1 up, 0 down | May 11, 2026 |
| Dec 31, 2025 | -$0.29 | -$0.24 | -$0.24 - -$0.24 | -20.83% | Miss | N/A | 1 | 0 up, 1 down | Mar 17, 2026 |
| Sep 30, 2025 | -$0.31 | -$0.22 | -$0.23 - -$0.21 | -40.91% | Miss | N/A | 2 | 0 up, 0 down | Nov 12, 2025 |
| Jun 30, 2025 | -$0.21 | -$0.31 | -$0.31 - -$0.31 | +32.26% | Beat | N/A | 1 | 1 up, 0 down | Aug 12, 2025 |
| Mar 31, 2025 | -$0.35 | -$0.27 | -$0.27 - -$0.25 | -29.63% | Miss | N/A | 2 | 1 up, 0 down | May 13, 2025 |
| Dec 31, 2024 | -$0.25 | -$0.27 | N/A | +7.41% | Beat | N/A | 1 | 0 up, 0 down | Mar 25, 2025 |
| Sep 30, 2024 | -$0.35 | -$0.39 | -$0.42 - -$0.32 | +10.26% | Beat | N/A | 3 | 0 up, 0 down | Nov 13, 2024 |
| Jun 30, 2024 | -$0.48 | -$0.59 | -$0.65 - -$0.51 | +18.64% | Beat | N/A | 4 | 0 up, 0 down | Aug 13, 2024 |
| Mar 31, 2024 | -$0.56 | -$0.62 | -$0.67 - -$0.56 | +9.68% | Beat | N/A | 4 | 0 up, 0 down | May 14, 2024 |
| Dec 31, 2023 | -$0.57 | -$0.75 | -$0.83 - -$0.69 | +24.00% | Beat | N/A | 4 | 0 up, 0 down | Mar 28, 2024 |
| Sep 30, 2023 | -$0.65 | -$0.63 | -$0.75 - -$0.56 | -3.17% | Miss | N/A | 3 | 2 up, 0 down | Nov 9, 2023 |
| Jun 30, 2023 | -$0.81 | -$0.85 | -$0.91 - -$0.80 | +4.71% | Beat | N/A | 3 | 0 up, 0 down | Aug 10, 2023 |
| Mar 31, 2023 | -$0.79 | -$0.68 | -$0.69 - -$0.66 | -16.18% | Miss | N/A | 3 | 0 up, 0 down | May 11, 2023 |
| Dec 31, 2022 | -$0.61 | -$0.65 | -$0.68 - -$0.61 | +6.15% | Beat | N/A | 3 | 0 up, 0 down | Mar 29, 2023 |
| Sep 30, 2022 | -$0.59 | -$0.60 | -$0.60 - -$0.58 | +1.67% | Beat | N/A | 3 | 0 up, 0 down | Nov 9, 2022 |
| Jun 30, 2022 | -$0.53 | -$0.47 | -$0.48 - -$0.42 | -12.77% | Miss | N/A | 3 | 0 up, 0 down | Aug 11, 2022 |
| Mar 31, 2022 | -$2.98 | -$0.51 | N/A | -484.31% | Miss | N/A | N/A | N/A | May 10, 2022 |
| Dec 31, 2021 | Not reported | N/A | N/A | N/A | Not reported | N/A | N/A | N/A | Mar 28, 2022 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$1.16, after -$1.64 the year before. It was -$4.71 for the year ended Dec 31, 2022, the oldest of the 4 fiscal years below with reported EPS.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$1.16 | N/A |
| Dec 31, 2024 | -$1.64 | N/A |
| Dec 31, 2023 | -$2.82 | N/A |
| Dec 31, 2022 | -$4.71 | N/A |
| Dec 31, 2021 | Not reported | N/A |
Frequently Asked Questions About ANTX
When is AN2 Therapeutics's next earnings date?
AN2 Therapeutics's next earnings report is expected for Mar 15, 2027.
Did ANTX beat earnings estimates last quarter?
Yes. AN2 Therapeutics reported EPS of -$0.17 for the quarter ended Sep 30, 2026, above the -$0.20 estimate, a 15.00% surprise.
What EPS do analysts expect from ANTX next quarter?
The consensus EPS estimate for AN2 Therapeutics for the quarter ending Dec 31, 2026 is -$0.24 from 4 analysts, with estimates from -$0.25 to -$0.22.
How often does ANTX beat earnings estimates?
AN2 Therapeutics beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of -4.72%.
ANTX pages: Overview, Earnings, Forecast, Financials, Competitors, Government Contracts